Christopher Hunt Keir

Author

The University of Texas MD Anderson Cancer Center

Also Known As

C. H. Keir, C. Keir, Christopher H Keir, Christopher H. Keir, Christopher Hunt Keir, Christopher Keir, Keir, Christopher

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center National Cancer Center Hospital East Hammersmith Hospital Oslo University Hospital

About

Christopher Hunt Keir is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacotherapy, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	101
2	Health Sciences	3	3	70
3	Immunology	1	1	20
4	Molecular Medicine	1	1	20
5	Neurology	1	1	31

Christopher Hunt Keir

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer Scott Kopetz, Axel Grothey, Rona Yaeger, New England Journal of Medicine	2019	1.4K
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase Annie Guérin, Lei Chen, Raluca Ionescu‐Ittu, Current Medical Research and Opinion	2014	67
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study Jörge E. Cortes, Jeffrey H. Lipton, Carole B. Miller, Clinical Lymphoma Myeloma & Leukemia	2016	35
Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin Kenneth Lawrence, May Adra, Christopher Hunt Keir Journal of Infection Hypoxia (Medicine)NeuropharmacologyNeuroprotectionNeurologyBrain Injury	2005	31
Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia Alessandro Crotta, Jie Zhang, Christopher Hunt Keir Current Medical Research and Opinion	2017	29
Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Scott Kopetz, Axel Grothey, Eric Van Cutsem, Journal of Clinical Oncology Cancer ManagementPathologyPharmacotherapyLogistic AnalysisBeacon Crc Study	2020	27
Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Scott Kopetz, Axel Grothey, Eric Van Cutsem, Journal of Clinical Oncology Cancer ManagementPathologyPharmacotherapyLogistic AnalysisBeacon Crc Study	2020	23
Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection Annie Guérin, Medha Sasané, Christopher Hunt Keir, JAMA Oncology	2015	20
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. Francois-Xaxier Mahon, Michele Baccarani, Michael J. Mauro, Journal of Clinical Oncology T-regulatory CellImmunologyPathologyPharmacotherapyImmunotherapy	2014	20
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy Annie Guérin, Medha Sasané, Geneviève Gauthier, Journal of Medical Economics	2014	11

Page 1